buyModerate
SPRINGER TIMOTHY A bought $7.4M of RNAC
director, owner at Cartesian Therapeutics, Inc.. 431,940 shares at an average of $17.07, traded Nov 14, 2024, filed Nov 18, 2024.
Conviction score
43Value
$7.4M
431,940 shares
Holdings after
8,455,706
+5% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001453687-24-000134, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 14, 2024 | POpen-market purchase Common Stock | +74,157 | $16.19 | $1.2M | 8,097,923 | Nov 18, 2024 |
| Nov 14, 2024 | POpen-market purchase Common Stock | +22,242 | $16.97 | $377k | 8,120,165 | Nov 18, 2024 |
| Nov 15, 2024 | POpen-market purchase Common Stock | +277,246 | $17.09 | $4.7M | 8,397,411 | Nov 18, 2024 |
| Nov 18, 2024 | POpen-market purchase Common Stock | +38,114 | $17.96 | $684k | 8,435,525 | Nov 18, 2024 |
| Nov 18, 2024 | POpen-market purchase Common Stock | +20,181 | $18.42 | $372k | 8,455,706 | Nov 18, 2024 |
Related signals
Other insiders at Cartesian Therapeutics, Inc. and this insider’s other filings.
| Score | Side | Company | Insider | Value | Shares | Filed |
|---|---|---|---|---|---|---|
| 40Moderate | buy | RNAC Cartesian Therapeutics, Inc. | SPRINGER TIMOTHY A director, owner | $965k | 52,189 | |
| 20Weak | sell | RNAC Cartesian Therapeutics, Inc. | Kurtoglu Metin Chief Technology Officer | $345k | 13,664 | |
| 55Moderate | sell 3 | RNAC Cartesian Therapeutics, Inc. | Kurtoglu Metin Chief Technology Officer | $649k | 38,689 | |
| 58Moderate | sell 3 | RNAC Cartesian Therapeutics, Inc. | Jewell Christopher M Chief Scientific Officer | $875k | 52,115 | |
| 59Moderate | sell 3 | RNAC Cartesian Therapeutics, Inc. | Miljkovic Milos Chief Medical Officer | $908k | 55,000 | |
| 60Notable | sell 3 | RNAC Cartesian Therapeutics, Inc. | Kurtoglu Metin Chief Technology Officer | $1.4M | 82,368 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.